It has gone extremely well. We launched the product into the marketplace two or three years ago. It's a web portal.
As you know, we publish the big blue book, the Compendium of Pharmaceuticals and Specialties, which is a collection of Health Canada product monographs. We also publish a book called Therapeutic Choices, which is like a set of clinical guidelines to drug use in particular diseases. As for what e-Therapeutics is, we actually integrate the content from those two publications and make them available online.
So the system is working. It's working very well.
For a physician who is treating a particular disease and wants some information, it recommends drugs that could be used, but then the physician can click on that drug and go to the full monograph to get information. The important value of it as well is that we are able to incorporate advisories from Health Canada directly into that system. So in the example we had about the warning from Australia about the risks of serious hepatic adverse drug reactions associated with the non-steroidal anti-inflammatory drug, as soon as Health Canada issued that advisory, we had it on our website being delivered to those physicians, pharmacists, hospitals, and institutions that subscribe to our e-Therapeutics product.
The uptake has actually been slower than what we had anticipated. As you know, the funding was issued on the basis of it being a sustainable business model. We're close to sustainability, but one of the things that are hampering uptake a little bit is the delay that we've seen in the implementation of provincial drug information systems. But the system has been incredibly well received by practitioners.